Viral Hepatitis Prevention Priorities

At a glance

The Division of Viral Hepatitis (DVH) 2025 Strategic Plan articulates vision, mission, core values, and goals. Each goal is further defined by specific and time-bound outcome measures and supporting objectives and associated strategies.

Division of Viral Hepatitis

About the viral hepatitis strategic plan

Vision

A world without viral hepatitis

Mission

To end the viral hepatitis epidemics through leadership in science and public health practices

Goals

  1. Reduce new viral hepatitis infections
  2. Reduce viral hepatitis-related morbidity and mortality
  3. Reduce viral hepatitis-related disparities
  4. Establish comprehensive national viral hepatitis surveillance for public health action

Objectives and indicators of progress

Baseline, 2025 goals, 2030 goals

Category Baseline 2025 Goals
(% ↓ or ↑)*		 2030 Goals
(% ↓ or ↑)*		 Approximate %
↓ or ↑*
for 2025/2030
Goal 1: Reduce new viral hepatitis infections (estimated cases)
Hepatitis A 6,700 ≤ 4,000 (↓40%) ≤ 2,500 (↓63%) ↓40%/↓65%
Acute hepatitis B 22,200 ≤ 18,000 (↓19%) ≤ 2,200 (↓90%) ↓20%/↓90%
Acute hepatitis C 44,700 ≤ 35,000 (↓22%) ≤ 4,400 (↓90%) ↓20%/↓90%
Goal 2: Reduce viral hepatitis-related morbidity and mortality (reported death rates)
Hepatitis B-related 0.46 ≤ 0.37 (↓20%) ≤ 0.16 (↓65%) ↓20%/↓65%
Hepatitis C-related 4.13 ≤ 3.00 (↓27%) ≤ 1.44 (↓65%) ↓25%/↓65%
Goal 3: Reduce viral hepatitis-related disparities (reported case rates)
New hepatitis B,
PWID≠		 1.4 ≤ 1.0 (↓29%) ≤ 0.1 (↓93%) ↓25%/↓90%
New hepatitis C,
PWID≠		 2.3 ≤ 1.7 (↓26%) ≤ 0.2 (↓90%) ↓25%/↓90%
Hepatitis B-related
deaths, A/PIs		 2.45 ≤ 1.84 (↓25%) ≤ 0.86 (↓65%) ↓25%/↓65%
Hepatitis C-related
deaths, AI/ANs		 10.24 ≤ 7.17 (↓30%) ≤ 3.58 (↓65%) ↓30%/↓65%
Hepatitis C-related
deaths,
non-Hispanic Blacks		 7.03 ≤ 4.92 (↓30%) ≤ 2.46 (↓65%) ↓30%/↓65%
Indicators of Progress
1.3: Hepatitis B birth
dose (0–1 day)		 67%
(2015–2016
birth years)		 ≥ 75% (↑12%)
(2021–2022
birth years)		 ≥ 90% (↑34%)
(2026–2027
birth years)		 ↑10% (2021–2022
birth years)/↑35%
(2026–2027 birth years)
2.1: % Hepatitis B
aware of infection		 32%
(2013–2016)		 ≥ 50% (↑56%)
(2021–2024)		 ≥ 90% (↑181%)
(2025–2028)		 ↑55% (2021–2024)/
↑180% (2025–2028)
2.3: % Hepatitis B
engaged in care		 26%
(2013–2016)		 ≥ 40% (↑54%)
(2021–2024)		 ≥ 80% (↑208%)
(2025–2028)		 ↑55% (2021–2024)/
↑210% (2025–2028)
2.4: % Hepatitis C
viral clearance		 43%
(2013–2016)		 ≥ 58% (↑35%)
(2021–2024)		 ≥ 80% (↑86%)
(2025–2028)		 ↑35% (2021–2024)/
↑85% (2025–2028)

Note: Unless otherwise noted, baseline data are from 2017, 2025 goals are based on 2023 data, and 2030 goals are based on
2028 data. Rates are per 100,000 population.
*Reductions are compared to 2017, unless otherwise noted.
≠18–40-year-olds serve as a proxy for persons who inject drugs (PWID).
A/PIs = Asians and Pacific Islanders; AI/ANs = American Indians and Alaska Natives

Data sources

Goal / Indicator of Progress* Hepatitis Virus Data Source Data Utilized
Baseline 2025 Goals 2030 Goals
New infections A, B, C NNDSS 2017 2023 2028
Birth dose vaccination B NIS - Child 2015–2016 birth years 2021–2022 birth years 2026–2027 birth years
Deaths B, C NVSS 2017 2023 2028
Awareness of infection B NHANES 2013–2016 2021–2024 2025–2028
Engagement in care B NHANES 2013–2016 2021–2024 2025–2028
Viral clearance C NHANES 2013–2016 2021–2024 2025–2028
NNDSS = National Notifiable Diseases Surveillance System; NIS - Child = National Immunization Survey-Child (children 19 to 35 months old); NVSS = National Vital Statistics System; NHANES = National Health and Nutrition Examination Survey. *Indicators of Progress are quantitative measures available for certain objectives.
Print
Content Source:
National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention
  • * 18-40 year-olds serve as a proxy for PWID
  • AI/ANs = American Indians and Alaska Natives
  • A/PIs = Asians and Pacific Islanders
  • PWID = people who inject drugs